Comparing the current results to its competitors, Tscan Therapeutics Inc reported Revenue decrease in the 1 quarter 2026 year on year by -54.77 %, despite the revenue increase by the most of its competitors of 122.08 %, recorded in the same quarter.
Tscan Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 15.44 %
Tscan Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment within the biopharmaceutical and cell therapy sectors, facing competition from large and specialty biopharmaceutical firms, academic and governmental research institutions, and both public and private research organizations. Competitors vie for personnel, clinical site establishment, patient recruitment, and acquisition of complementary technologies. The company specifically competes with TCR-based firms including Immatics N.V., Adaptimmune Therapeutics, Plc. (which sold its cell therapy assets to US WorldMeds, LLC in July 2025), Affini-T Therapeutics, Inc., Medigene AG (which initiated insolvency proceedings in April 2025), T-Knife GmbH, Immunocore Holdings, Plc., and 3T Biosciences Inc. Additional competition arises from companies developing other T cell therapies, such as Iovance Biotherapeutics, Inc., Instil Bio, Inc., and Kite Pharma, Inc., a subsidiary of Gilead, Inc. The company also encounters broader competition across the oncology market from various cancer treatment methods and drug therapies.
September 3, 2025
TScan Therapeutics: Strategic Participation in Investor Conferences Amid Mixed Market Performance TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology firm headquartered in Waltham, Massachusetts, is making strategic moves to engage with investors at several upcoming conferences this month. The company, which is at the forefront of developing T cell receptor (TCR)-engineered T cell therapies aimed at treating cancer, sees these conferences as a platform to share developments and future plans with the investment community.TScan s commitment to advancing TCR-T therapies mirrors the broader industry trend towards innovative cancer treatments involving engineered cells. TCR-T therapies are gai...
Adaptimmune Therapeutics Plc is a biopharmaceutical company that focuses on developing and commercializing innovative cancer immunotherapy products. Their business model revolves around leveraging their T-cell receptor platform to engineer and develop targeted immunotherapies for patients with various types of cancer.
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Intensity Therapeutics Inc's business model involves developing and commercializing novel intratumoral cancer immunotherapy products. They aim to target and destroy tumors within the body through the direct application of their proprietary drug, leading to an enhanced immune response and potential treatment for various cancers.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Century Therapeutics Inc. is a biotechnology company that aims to develop novel cell therapies targeting various diseases. Their business model focuses on leveraging induced pluripotent stem cell (iPSC) technology to engineer cellular therapies and bring them to market, with a specific emphasis on treating cancer.
Sources:
Tscan Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tscan Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
